CN102083801A - 喹唑啉衍生物和治疗方法 - Google Patents

喹唑啉衍生物和治疗方法 Download PDF

Info

Publication number
CN102083801A
CN102083801A CN2009801188299A CN200980118829A CN102083801A CN 102083801 A CN102083801 A CN 102083801A CN 2009801188299 A CN2009801188299 A CN 2009801188299A CN 200980118829 A CN200980118829 A CN 200980118829A CN 102083801 A CN102083801 A CN 102083801A
Authority
CN
China
Prior art keywords
compound
deuterium
cancer
hydrogen
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801188299A
Other languages
English (en)
Chinese (zh)
Inventor
克雷格·E·马斯
罗杰·滕格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of CN102083801A publication Critical patent/CN102083801A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2009801188299A 2008-03-28 2009-03-27 喹唑啉衍生物和治疗方法 Pending CN102083801A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4064708P 2008-03-28 2008-03-28
US61/040,647 2008-03-28
US15754909P 2009-03-04 2009-03-04
US61/157,549 2009-03-04
PCT/US2009/038701 WO2009121042A1 (en) 2008-03-28 2009-03-27 Quinazoline derivatives and methods of treatment

Publications (1)

Publication Number Publication Date
CN102083801A true CN102083801A (zh) 2011-06-01

Family

ID=40638034

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801188299A Pending CN102083801A (zh) 2008-03-28 2009-03-27 喹唑啉衍生物和治疗方法

Country Status (5)

Country Link
US (1) US20090269354A1 (enExample)
JP (1) JP2011516426A (enExample)
KR (1) KR20110005828A (enExample)
CN (1) CN102083801A (enExample)
WO (1) WO2009121042A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103536925A (zh) * 2013-10-28 2014-01-29 中国医学科学院基础医学研究所 强心苷化合物在非小细胞肺癌治疗中的应用
CN106188072A (zh) * 2015-05-07 2016-12-07 刘文沛 氘代4-[(3-乙炔苯基)氨基]-6,7-苯-12冠-4-喹唑啉衍生物以及包含该衍生物的药物组合物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
US20110195066A1 (en) * 2010-02-05 2011-08-11 Auspex Pharmaceuticals, Inc. Quinoline inhibitors of tyrosine kinase
WO2011133826A2 (en) * 2010-04-23 2011-10-27 Niiki Pharma Inc. Method for treating pancreatic cancer
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
WO2014028914A1 (en) * 2012-08-17 2014-02-20 Beta Pharma, Inc. Deuterated icotinib derivatives
US9192609B2 (en) * 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
WO2020136650A1 (en) * 2018-12-25 2020-07-02 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an egfr inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1110953A1 (en) * 1995-03-30 2001-06-27 Pfizer Inc. Quinazoline derivatives
US6476040B1 (en) * 1999-03-31 2002-11-05 Pfizer Inc. Processes and intermediates for preparing anti-cancer compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL259609A (enExample) * 1959-12-31
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
OA12542A (en) * 2001-01-31 2006-06-05 Pfizer Prod Inc Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4isozymes.
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
AU2005249201A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with irinotecan (CPT-11) and an EGFR-inhibitor
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
AU2007288204A1 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-aminoquinazoline derivatives and methods of use thereof
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US8343950B2 (en) * 2006-12-15 2013-01-01 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1110953A1 (en) * 1995-03-30 2001-06-27 Pfizer Inc. Quinazoline derivatives
US6476040B1 (en) * 1999-03-31 2002-11-05 Pfizer Inc. Processes and intermediates for preparing anti-cancer compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D.J.KUSHNER ET AL.: "Pharmacological uses and perspectives of heavy water and deuterated compounds", 《CAN.J.PHYSIOL.PHARMACOL》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103536925A (zh) * 2013-10-28 2014-01-29 中国医学科学院基础医学研究所 强心苷化合物在非小细胞肺癌治疗中的应用
CN103536925B (zh) * 2013-10-28 2015-07-01 中国医学科学院基础医学研究所 强心苷化合物在非小细胞肺癌治疗中的应用
CN106188072A (zh) * 2015-05-07 2016-12-07 刘文沛 氘代4-[(3-乙炔苯基)氨基]-6,7-苯-12冠-4-喹唑啉衍生物以及包含该衍生物的药物组合物

Also Published As

Publication number Publication date
KR20110005828A (ko) 2011-01-19
WO2009121042A8 (en) 2010-11-25
JP2011516426A (ja) 2011-05-26
US20090269354A1 (en) 2009-10-29
WO2009121042A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
US7855204B2 (en) Derivatives of gefitinib
US8343950B2 (en) Quinazoline derivatives and methods of treatment
CN102083801A (zh) 喹唑啉衍生物和治疗方法
US8921366B2 (en) Substituted triazolo-pyridazine derivatives
RU2694252C2 (ru) Производные 4-(замещенного фениламино)хиназолина или их фармацевтически приемлемые соли, способ ингибирования рецепторной тирозинкиназы и фармацевтическая композиция
JP5830573B2 (ja) 置換キナゾリン誘導体およびチロシンキナーゼインヒビターとしてのそれらの使用
US8575221B2 (en) Derivatives of dimethylcurcumin
US8609673B2 (en) Vandetanib derivatives
TW200528111A (en) Pyrido-and pyrimidopyrimidine derivatives
TW201305131A (zh) 治療化合物及組成物
TW201245160A (en) Quinazoline derivatives
JP2004517048A (ja) キナゾリン誘導体、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法
WO2009094211A1 (en) Quinazoline compounds and methods of treating cancer
CN106432202A (zh) 喹唑啉类衍生物及其应用
WO2010019701A2 (en) Diaryl urea derivatives
WO2010065755A1 (en) Deuterated pyridinones
US8410082B2 (en) Fluorinated diaryl urea derivatives
US20100260674A1 (en) Quinazoline derivatives and methods of treatment
HK1154508A (en) Quinazoline derivatives and methods of treatment
US20110301113A1 (en) Pyridineamine derivatives
CN107501283B (zh) 取代芳甲杂基取代苯胺基缩乙二醇醚环代喹唑啉的制备及肿瘤治疗药物应用
WO2020092604A1 (en) Deuterated pitolisant

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1154508

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110601

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1154508

Country of ref document: HK